Targeting the epidermal growth factor receptor: Prognostic and clinical implications

European Journal of Cancer, Supplement

Volumn 1, Issue 8 SPEC. ISS., 2003, Pages 9-15

  Herbst, Roy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Gefitinib; Iressa; Prognostic factors; ZD1839

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MARIMASTAT; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; PICIBANIL; PROTEIN DERIVATIVE; PROTEIN TYROSINE KINASE; TAMOXIFEN;

CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG POTENCY; DRUG TARGETING; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SKIN TOXICITY; STATISTICAL SIGNIFICANCE;

EID: 0346649812     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(03)80015-0     Document Type: Article

References (32)

1. Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal. 1:2000;12-21
2. Wells A. The epidermal growth factor receptor (EGFR) - a new target in cancer therapy. Signal. 1:2000;4-11
3. Raymond E., Faivre S., Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 60:(Suppl 1):2000;15-23
4. Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur J Cancer. 37:(Suppl 4):2001;S9-S15
5. Moscatello D.K., Holgado-Madruga M., Godwin A.K., et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55:1995;5536-5539
6. Olapade-Olaopa E.O., Moscatello D.K., MacKay E.H., et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer. 82:2000;186-194
7. Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 7:2001;1459-1465
8. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 7:2001;2958-2970
9. Mandal M., Adam L., Wang R.-A., et al. Inhibition of P21-activated kinase 1, directional cell motility and invasion of growth-factor-activated human cancer cells by the selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa'). Poster presentation at the AACR. San Francisco :April 6-10, 2002;. (poster 786)
10. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 6:2000;2053-2063
11. Sirotnak F.M., Zakowsky M.F., Miller V.A., Scher H.I., Kris M.G. Potentiation of cytotoxic agents against human tumors in mice by ZD1839 (Iressa™), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR. Proc Am Assoc Cancer Res. 41:2000;482. (abstract 3076)
12. Nakagawa K., Tamura T., Negoro S., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol. 14:2003;922-930
13. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:2002;4292-4302
14. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 20:2002;2240-2250
15. Herbst R.S., Maddox A.M., Rothenberg M.L., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 20:2002;3815-3825
16. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 21:2003;2237-2246
17. Kris M.G., Natale R.B., Herbst R.S., et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol. 21:2002;292a. (abstract 1166)
18. Bailey L.R., Kris M., Wolf M., et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib ('Iressa', ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res. 44:2003;. (abstract LB-170)
19. Janas M.S., Franklin W.A., Schmidt K., Bailey L.R. Interobserver reproducibility of visually interpreted EGFR immunohistochemical staining in non-small-cell lung cancer. Proc Am Assoc Cancer Res. 44:2003;. (abstract LB-213)
20. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature. 411:2001;355-365
21. Aaronson S.A. Growth factors and cancer. Science. 254:1991;1146-1153
22. Natale R.B., Shak S., Aronson N., et al. Quantitative gene expression in non-small cell lung cancer from paraffin-embedded tissue specimens: Predicting response to gefitinib, an EGFR kinase inhibitor. Proc Am Soc Clin Oncol. 22:2003;190. (abstract 763)
23. Suzuki C., Daigo Y., Kakiuchi S., Zembutzu H., Furukawa C., Nakamura Y. Identification of genes associated with sensitivity to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer cell lines and tumor xenografts. Proc Am Assoc Cancer Res. 44:2003;. (abstract 3773)
24. Brundage M.D., Davies D., Mackillop W.J. Prognostic factors in non-small cell lung cancer. A decade of progress. Chest. 122:2002;1037-1057
25. Huisman C., Smit E.F., Giaccone G., Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol. 18:2000;3722-3730
26. Giaccone G., Johnson D., Scagliotti G.V., et al. Results of a multivariate analysis of prognostic factors for overall survival of patients with advanced non-small-cell lung cancer treated with gefitinib ('Iressa', ZD1839) in combination with platinum-based chemotherapy in two large phase III trials (INTACT 1 and INTACT 2). Poster presentation at ASCO. Chicago, IL, USA :May 31-June 3, 2003;. (poster 2522)
27. Cohen E.E.W., Rosen F., Stadler W.M., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 21:2003;1980-1987
28. Jänne P.A., Gurubhagavatula S., Lucca J., et al. Clinical benefits in patients with advanced non-small-cell lung cancer treated with gefitinib in the compassionate use programme. Abstract presented at the 10th WCLC. Vancouver, Canada :August 10-14, 2003;. (abstract O-243)
29. Perez-Soler R., Chachoua A., Huberman M., et al. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 20:2001;310a. (abstract 1235)
30. Kies M.S., Arquette M.A., Nabell L. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck to cisplatin containing chemotherapy. Proc Am Soc Clin Oncol. 21:2002;232a. (abstract 925)
31. Baselga J., Yano S., Giaccone G., et al. Initial results from a Phase II trial of ZD1839 ('Iressa') as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). Poster presentation at the AACR-NCI-EORTC. Miami Beach, Florida, USA :October 29-November 2, 2001;. (poster 630A)
32. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol. 20:2002;110-124